The Takeda spinoff is developing a vaccine for acute gastroenteritis caused by norovirus infection, and raised about $140m in August 2021.
HilleVax, a US-based vaccine developer spun off by pharmaceutical firm Takeda, has filed for an initial public offering on the Nasdaq Global Select Market.
Formed as a collaboration between Takeda and venture capital firm Frazier Healthcare Partners, HilleVax is working on a vaccine for norovirus infection-triggered acute gastroenteritis.
HilleVax’s lead product candidate, HIL-214, has already undergone several clinical tests under Takeda’s auspices, but the company has transferred the open investigational new drug application for it to HilleVax, which now…
